News | January 14, 2023
Global (68M) cardiomyopathies market set to reach $9.63 bn by 2031: GlobalData
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
Global pharmaceutical company having a surgical business concept incepted in Dubai
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
To focus on providing safer burn treatments for women and armed forces
Silodosin capsules treat signs and symptoms of an enlarged prostate gland
GlobalData predicts the average prices of dual chamber pacemakers in both India and China are expected to reduce at an average CAGR of -3.42% from 2022 to 2025.
The use of procalcitonin testing for sepsis management is highest in the US
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
Subscribe To Our Newsletter & Stay Updated
